Ascendis Pharma A/S (ASND) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
United Therapeutics (UTHR) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 19.3% versus a gain of 8.8%. Over five years, UTHR leads with a +191.3% price change compared with +42.8% for ASND. United Therapeutics is the larger company by market cap ($23.04 billion vs $14.96 billion), about 1.5 times the size.
On valuation, United Therapeutics trades at a lower forward P/E (17.2x vs 21.0x for Ascendis Pharma A/S).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | UTHR |
|---|---|---|
| Share price | $227.29 | $537.30 |
| Market cap | $14.96B | $23.04B |
| 1-day change | -0.49% | -1.41% |
| YTD return | +7.11% | +11.85% |
| 1-year return | +8.84% | +19.30% |
| 5-year return | +42.77% | +191.33% |
| P/E ratio (TTM) | 17.42 | 19.24 |
| Forward P/E | 21.00 | 17.18 |
| EPS (TTM) | $13.05 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.18B |
| Revenue growth (YoY) | — | +10.61% |
| Net income (latest FY) | — | $1.33B |
| Gross margin | — | 87.92% |
| Operating margin | — | 46.89% |
| Net margin | — | 41.94% |
| 52-week high | $282.15 | $609.35 |
| 52-week low | $186.05 | $409.07 |
| Distance from 52-week high | -19.44% | -11.82% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +34.56% | +20.91% |
| Average volume | 658.78K | 655.10K |
| Shares outstanding | 65.80M | 42.89M |
| Employees | 1,189 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UTHR has outperformed ASND by 10.5 percentage points over the past year.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
ASND vs UTHR FAQ
Which is bigger, Ascendis Pharma A/S or United Therapeutics?
United Therapeutics (UTHR) is larger, with a market capitalization of $23.04B compared with $14.96B for Ascendis Pharma A/S (ASND).
Which stock has performed better over the past year, ASND or UTHR?
UTHR returned +19.30% over the past 12 months, compared with +8.84% for ASND (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASND or UTHR?
ASND has the lower trailing P/E at 17.4, versus 19.2 for UTHR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ascendis Pharma A/S and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.